{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:25:37Z","timestamp":1789118737242,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["168896"],"award-info":[{"award-number":["168896"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02163-7","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:10:35Z","timestamp":1779433835000},"page":"1904-1914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral anticoagulant switching in patients with atrial fibrillation: a long-term cohort study using population-level administrative data"],"prefix":"10.1007","volume":"48","author":[{"given":"Adenike R.","family":"Adelakun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky D.","family":"Turgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"De Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"McGrail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdollah","family":"Safari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Loewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"2","key":"2163_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/bcp.14171","volume":"86","author":"C Kennedy","year":"2020","unstructured":"Kennedy C, Choitir CN, Clarke S, et al. Direct oral anticoagulants uptake and an oral anticoagulation paradox. Br J Clin Pharmacol. 2020;86(2):392\u20137. https:\/\/doi.org\/10.1111\/bcp.14171.","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"2163_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Aw B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. https:\/\/doi.org\/10.1161\/jaha.120.017559.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2163_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149(1):e1\u2013156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","journal-title":"Circulation"},{"issue":"36","key":"2163_CR4","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"issue":"12","key":"2163_CR5","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","volume":"36","author":"JG Andrade","year":"2020","unstructured":"Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol. 2020;36(12):1847\u2013948. https:\/\/doi.org\/10.1016\/j.cjca.2020.09.001.","journal-title":"Can J Cardiol"},{"issue":"38","key":"2163_CR6","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962. https:\/\/doi.org\/10.1093\/eurheartj\/ehw210.","journal-title":"Eur Heart J"},{"issue":"2","key":"2163_CR7","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.15586\/jptcp.v27i2.662","volume":"27","author":"A Holbrook","year":"2020","unstructured":"Holbrook A, Morrow R, Lee AYY, et al. Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: a retrospective cohort study. J Popul Ther Clin Pharmacol. 2020;27(2):e28\u201344. https:\/\/doi.org\/10.15586\/jptcp.v27i2.662.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"2","key":"2163_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s11239-020-02367-2","volume":"52","author":"M Romoli","year":"2021","unstructured":"Romoli M, Marchetti G, Bernardini F, et al. Switching between direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Thrombolysis. 2021;52(2):560\u20136. https:\/\/doi.org\/10.1007\/s11239-020-02367-2.","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2163_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071907","volume":"13","author":"AR Adelakun","year":"2023","unstructured":"Adelakun AR, Turgeon RD, De Vera MA, et al. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review. BMJ Open. 2023;13(4):e071907. https:\/\/doi.org\/10.1136\/bmjopen-2023-071907.","journal-title":"BMJ Open"},{"issue":"7","key":"2163_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jacc.2016.11.061","volume":"69","author":"MV Huisman","year":"2017","unstructured":"Huisman MV, Rothman KJ, Paquette M, et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol. 2017;69(7):777\u201385. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.061.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2163_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.026723","volume":"11","author":"AM Navar","year":"2022","unstructured":"Navar AM, Kolkailah AA, Overton R, et al. Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J Am Heart Assoc. 2022;11(22):e026723. https:\/\/doi.org\/10.1161\/jaha.122.026723.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2163_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.007129","volume":"6","author":"AYX Yu","year":"2017","unstructured":"Yu AYX, Malo S, Svenson LW, et al. Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population\u2010based study. J Am Heart Assoc. 2017;6(11):e007129. https:\/\/doi.org\/10.1161\/jaha.117.007129.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2163_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1345\/aph.1k671","volume":"43","author":"BC Martin","year":"2009","unstructured":"Martin BC, Wiley-Exley EK, Richards S, et al. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36\u201344. https:\/\/doi.org\/10.1345\/aph.1k671.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"2163_CR14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/nejmoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/nejmoa0905561.","journal-title":"N Engl J Med"},{"issue":"6","key":"2163_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102544","volume":"8","author":"TAC de Vries","year":"2024","unstructured":"de Vries TAC, Bavalia R, Chu G, et al. Prescription and switching patterns of direct oral anticoagulants in patients with atrial fibrillation. Res Pract Thromb Haemost. 2024;8(6):102544. https:\/\/doi.org\/10.1016\/j.rpth.2024.102544.","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2163_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s1543-5946(04)90005-0","volume":"2","author":"MD Murray","year":"2004","unstructured":"Murray MD, Morrow DG, Weiner M, et al. A conceptual framework to study medication adherence in older adults. Am J Geriatr Pharmacother. 2004;2(1):36\u201343. https:\/\/doi.org\/10.1016\/s1543-5946(04)90005-0.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"9","key":"2163_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/ajh\/hpab046","volume":"34","author":"M Krousel-Wood","year":"2021","unstructured":"Krousel-Wood M, Craig LS, Peacock E, et al. Medication adherence: expanding the conceptual framework. Am J Hypertens. 2021;34(9):895\u2013909. https:\/\/doi.org\/10.1093\/ajh\/hpab046.","journal-title":"Am J Hypertens"},{"key":"2163_CR18","first-page":"SP309","volume":"24","author":"SL Wong","year":"2018","unstructured":"Wong SL, Marshall LZ, Lawson KA. Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas Medicaid. Am J Manag Care. 2018;24:SP309\u201314.","journal-title":"Am J Manag Care"},{"issue":"2","key":"2163_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.23889\/ijpds.v5i1.1133","volume":"4","author":"T Ark","year":"2019","unstructured":"Ark T, Kesselring S, Hills B, et al. Population data BC: supporting population data science in British Columbia. Int J Popul Data Sci. 2019;4(2):1133. https:\/\/doi.org\/10.23889\/ijpds.v5i1.1133.","journal-title":"Int J Popul Data Sci"},{"issue":"1","key":"2163_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ahj.2014.09.014","volume":"169","author":"AM Navar-Boggan","year":"2015","unstructured":"Navar-Boggan AM, Rymer JA, Piccini JP, et al. Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. Am Heart J. 2015;169(1):39-44.e2. https:\/\/doi.org\/10.1016\/j.ahj.2014.09.014.","journal-title":"Am Heart J"},{"issue":"Suppl 1(S1)","key":"2163_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pds.2317","volume":"21","author":"PN Jensen","year":"2012","unstructured":"Jensen PN, Johnson K, Floyd J, et al. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1(S1)):141\u20137. https:\/\/doi.org\/10.1002\/pds.2317.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2163_CR22","unstructured":"British Columbia Ministry of Health. Limited Coverage Drugs\u2014Apixaban for atrial fibrillation. Available at: https:\/\/web.archive.org\/web\/20211101060337\/https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/prescribers\/limited-coverage-drug-program\/limited-coverage-drugs-apixaban-for-atrial-fibrillation-af. Accessed 01 Nov 2021."},{"issue":"4","key":"2163_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"2163_CR24","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.jval.2021.04.1210","volume":"24","author":"S Salmasi","year":"2021","unstructured":"Salmasi S, H\u00f6egg T, Safari A, et al. SM1 The Random Effects Warfarin Days\u2019 Supply (REWARDS) Model: development and validation of a novel method to estimate exposure to warfarin using administrative data. Value Health. 2021;24:S241. https:\/\/doi.org\/10.1016\/j.jval.2021.04.1210.","journal-title":"Value Health"},{"issue":"11","key":"2163_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"issue":"1","key":"2163_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/strokeaha.116.015150","volume":"48","author":"I Hernandez","year":"2017","unstructured":"Hernandez I, Zhang Y, Brooks MM, et al. Anticoagulation use and clinical outcomes after major bleeding on Dabigatran or Warfarin in atrial fibrillation. Stroke. 2017;48(1):159\u201366. https:\/\/doi.org\/10.1161\/strokeaha.116.015150.","journal-title":"Stroke"},{"issue":"11","key":"2163_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.amjmed.2014.05.013","volume":"127","author":"NR Desai","year":"2014","unstructured":"Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation\u2014quality and cost implications. Am J Med. 2014;127(11):1075-1082.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2014.05.013.","journal-title":"Am J Med"},{"issue":"7","key":"2163_CR28","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/europace\/euw241","volume":"19","author":"M Hellfritzsch","year":"2017","unstructured":"Hellfritzsch M, Grove EL, Husted SE, et al. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. EP Eur. 2017;19(7):1091\u20135. https:\/\/doi.org\/10.1093\/europace\/euw241.","journal-title":"EP Eur"},{"issue":"6","key":"2163_CR29","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1093\/europace\/eux193","volume":"20","author":"EL Fosb\u00f8l","year":"2018","unstructured":"Fosb\u00f8l EL, Vinding NE, Lamberts M, et al. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation. EP Europace. 2018;20(6):e78\u201386. https:\/\/doi.org\/10.1093\/europace\/eux193.","journal-title":"EP Europace"},{"issue":"2","key":"2163_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11239-016-1452-2","volume":"43","author":"ZD Hale","year":"2017","unstructured":"Hale ZD, Kong X, Haymart B, et al. Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. J Thromb Thrombolysis. 2017;43(2):283\u20138. https:\/\/doi.org\/10.1007\/s11239-016-1452-2.","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"2163_CR31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00228-017-2296-1","volume":"73","author":"LJ Kjerpeseth","year":"2017","unstructured":"Kjerpeseth LJ, Ellekjaer H, Selmer R, et al. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol. 2017;73(11):1417\u201325. https:\/\/doi.org\/10.1007\/s00228-017-2296-1.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2163_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.joa.2017.05.008","volume":"33","author":"M Umei","year":"2017","unstructured":"Umei M, Kishi M, Sato T, et al. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. J Arrhythm. 2017;33(5):475\u201382. https:\/\/doi.org\/10.1016\/j.joa.2017.05.008.","journal-title":"J Arrhythm"},{"issue":"6","key":"2163_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/circulationaha.120.050438","volume":"143","author":"DJ Angiolillo","year":"2021","unstructured":"Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2021;143(6):583\u201396. https:\/\/doi.org\/10.1161\/circulationaha.120.050438.","journal-title":"Circulation"},{"issue":"3","key":"2163_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/heartjnl-2022-321114","volume":"109","author":"V Caso","year":"2023","unstructured":"Caso V, de Groot JR, Fernandez MS, et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart. 2023;109(3):178\u201385. https:\/\/doi.org\/10.1136\/heartjnl-2022-321114.","journal-title":"Heart"},{"key":"2163_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2025.101598","volume":"56","author":"M Yildirim","year":"2025","unstructured":"Yildirim M, Hund H, Mueller-Hennessen M, et al. Clinical impact of inappropriate DOAC dosing in atrial fibrillation: insights from a real-world registry. IJC Heart Vasc. 2025;56:101598. https:\/\/doi.org\/10.1016\/j.ijcha.2025.101598.","journal-title":"IJC Heart Vasc"},{"issue":"4","key":"2163_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11239-018-1719-x","volume":"46","author":"N Bernaitis","year":"2018","unstructured":"Bernaitis N, Badrick T, Davey AK, et al. Warfarin control in patients transitioning to warfarin after non-vitamin K oral anticoagulant (NOAC) therapy. J Thromb Thrombolysis. 2018;46(4):461\u20135. https:\/\/doi.org\/10.1007\/s11239-018-1719-x.","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"2163_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/clc.23376","volume":"43","author":"CT Sciria","year":"2020","unstructured":"Sciria CT, Maddox TM, Marzec L, et al. Switching warfarin to direct oral anticoagulants in atrial fibrillation: insights from the NCDR PINNACLE registry. Clin Cardiol. 2020;43(7):743\u201351. https:\/\/doi.org\/10.1002\/clc.23376.","journal-title":"Clin Cardiol"},{"issue":"10","key":"2163_CR38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/phar.2457","volume":"40","author":"TPP Nguyen","year":"2020","unstructured":"Nguyen TPP, Chen Y, Thibault D, et al. Impact of hospitalization and medication switching on post-discharge adherence to oral anticoagulants in patients with atrial fibrillation. Pharmacotherapy. 2020;40(10):1022\u201335. https:\/\/doi.org\/10.1002\/phar.2457.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"2163_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/circulationaha.123.066485","volume":"149","author":"LPT Joosten","year":"2024","unstructured":"Joosten LPT, van Doorn S, van de Ven PM, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2024;149(4):279\u201389. https:\/\/doi.org\/10.1161\/circulationaha.123.066485.","journal-title":"Circulation"},{"issue":"26","key":"2163_CR40","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1182\/bloodadvances.2017012377","volume":"1","author":"JK Schaefer","year":"2017","unstructured":"Schaefer JK, Sood SL, Haymart B, et al. Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. Blood Adv. 2017;1(26):2536\u201340. https:\/\/doi.org\/10.1182\/bloodadvances.2017012377.","journal-title":"Blood Adv"},{"issue":"1","key":"2163_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1074248419868996","volume":"25","author":"S Park","year":"2020","unstructured":"Park S, Je NK. Factors that affect time to switch from Warfarin to a direct oral anticoagulant after change in the reimbursement criteria in patients with atrial fibrillation. J Cardiovasc Pharmacol Ther. 2020;25(1):57\u201364. https:\/\/doi.org\/10.1177\/1074248419868996.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"2163_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/europace\/euu319","volume":"17","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17(4):530\u20138. https:\/\/doi.org\/10.1093\/europace\/euu319.","journal-title":"Europace"},{"issue":"2","key":"2163_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211681","volume":"14","author":"A Garcia-Sempere","year":"2019","unstructured":"Garcia-Sempere A, Hurtado I, Bejarano-Quisoboni D, et al. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K antagonists in Spain. A population-based, real-world study. PLoS ONE. 2019;14(2):e0211681. https:\/\/doi.org\/10.1371\/journal.pone.0211681.","journal-title":"PLoS ONE"},{"key":"2163_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/1179559x19831287","volume":"11","author":"A Rollins","year":"2019","unstructured":"Rollins A, Hanigan S, Pogue K, et al. Identifying clinical predictors of switching from direct oral anticoagulants to Warfarin. Clin Med Insights Ther. 2019;11:1179559X19831287. https:\/\/doi.org\/10.1177\/1179559x19831287.","journal-title":"Clin Med Insights Ther"},{"issue":"3","key":"2163_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.japh.2019.01.005","volume":"59","author":"PC Heaton","year":"2019","unstructured":"Heaton PC, Frede S, Kordahi A, et al. Improving care transitions through medication therapy management: a community partnership to reduce readmissions in multiple health-systems. J Am Pharm Assoc. 2019;59(3):319\u201328. https:\/\/doi.org\/10.1016\/j.japh.2019.01.005.","journal-title":"J Am Pharm Assoc"},{"issue":"8","key":"2163_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.7326\/0003-4819-155-8-201110180-00008","volume":"155","author":"LO Hansen","year":"2011","unstructured":"Hansen LO, Young RS, Hinami K, et al. Interventions to reduce 30-Day rehospitalization: a systematic review. Ann Intern Med. 2011;155(8):520\u20138. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00008.","journal-title":"Ann Intern Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02163-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:36Z","timestamp":1789117116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02163-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2163"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02163-7","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors have any conflicts of interest with this work.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Certificate of approval from the UBC Behavioral Research Ethics Board (H17-02420).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that patient consent is not applicable to this article. This is a retrospective cohort study using de-identified data; therefore, the research ethics body did not require consent from the patient.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual participants\u2019 identity was available to the authors, hence consent for publication has not been obtained from individuals.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}